Purpose: To evaluate the anti-tumour activity and tolerance of the combination of paclitaxel plus vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthracyclines.
Introduction
Metastatic breast cancer (MBC) belongs to the group of moderately sensitive, malignant tumours. Classical anthracycline combinations such as fluorouracil-adriamycin-cyclophosphamide (FAC), fluorouracil-epirubicin-cyclophosphamide (FEC) and adriamycin-cyclophosphamide (AC) are the most frequently used firstline regimens for MBC, and result in objective responses in 50%-80% of patients [1] . Most MBC patients who respond to first-line anthracycline-containing chemotherapy obtain partial or total relief of symptoms and, perhaps, moderate increase in survival time [2] . However, metastatic breast cancer remains, essentially, an incurable disease and the great majority of patients present with disease progression after the initial chemotherapy. The control of symptoms and palliation of MBC patients who progressed after an anthracyclinecontaining regimen constituted an important challenge for the clinician. Fortunately, new pharmacological agents, such as the taxanes and vinorelbine, have been introduced recently and have been shown to be partially non-cross resistant with anthracyclines in MBC [3, 4] . The availability of these drugs may offer some MBC patients who had had prior anthracycline exposure the possibility of a new anti-tumour response leading to symptom relief and, perhaps, a moderate improvement in survival time [5, 6] . To date, the best schedules and/or combinations of the new agents have not been well defined. In 1996, we commenced a co-operative phase II trial in which paclitaxel and vinorelbine were combined in treating MBC patients with prior anthracycline exposure. The rationale for this combination was based on the encouraging anti-tumour activity of paclitaxel (17%-29% response rate) and vinorelbine (16%-22% response rate) when used as single agents in MBC patients refractory to anthracyclines [3-5, 7, 8] . In addition, in vitro experiments indicated a synergistic effect of these two drugs when administered concurrently [9] [10] [11] .
Patients and methods
Eligibility criteria included: histologically proven breast cancer, progressive disease (measurable in at least one site), previous treatment with at least one anthracycline-containing regimen (as adjuvant therapy or for metastatic disease), Karnofsky performance status of 70 or more, life expectancy of at least two months, and adequate bone marrow, liver and renal function. Previous hormonal therapy was acceptable if it had been discontinued at least one month before chemotherapy. Patients who had received paclitaxel and/or vinorelbine before, as well as those who had previously received high-dose chemotherapy with stem-cell support, were not eligible for the trial.
In accordance with the institutional requirements of the two participating centres, signed informed consent was required from all patients indicating that they were aware of investigational nature of the study.
Baseline assessment included a full clinical history and thorough physical examination with a specific record kept of all measurable and assessable sites of neoplastic disease. Laboratory analysis included complete differential blood cell (CBC) counts, electrolytes, liver function tests (LFT) and chest X-ray. Additional radiographic studies (such as CTscans of lung and abdominal cavity) as well as photographs of all apparent cutaneous or nodal lesions were obtained as clinically indicated to document measurable disease.
CBC, electrolytes and LFT were performed at the beginning of each new course of therapy. Computed tomographies, chest X-rays, and photographs were repeated every three courses so as to document response to therapy.
Chemotherapy treatment consisted of paclitaxel (135 mg/m 2 infused over one hour) followed by vinorelbine (30 mg/m 2 over 10 minutes) on day 1. Patients received premedication with dexamethasone (20 mg i.v.), cimetidine (200 mg i.v.) and dexchlorpheniramine (5 mg i.v.) or another antihistamine drug just before paclitaxel administration. Chemotherapy treatment was repeated every three weeks provided that the patient had a neutrophil count of > 1500/ml and a platelet count of > 100,000/ml. In case of persistent myelosuppression (as measured on day 21), treatment was deferred until bone marrow recovery. Those patients presenting with neutropenic fever or grade 3 extra-haematological toxicity (except for peripheral neuropathy) were treated with a 25% dose reduction of both drugs over the remaining courses of proposed therapy. Therapy was discontinued in case of grade 3 or greater peripheral neuropathy.
Patients received at least three courses of paclitaxel plus vinorelbine before response was evaluated, except for those who had an overt progression of the disease after the first or the second course of treatment. For statistical purposes, the later patients were assigned as treatment failures and were considered assessable for response with respect to an intention-to-treat analysis. Patients with stable disease, partial response or complete response received the combination for a maximum of eight courses unless disease progressed and/or severe extramedulary toxicity was evidenced.
Response was categorised according to WHO criteria [12] , while toxicity was graded according to NCI common toxicity criteria (CTC). Anthracycline refractoriness was defined as no response to anthracycline-containing combinations or progressive disease during anthracycline therapy.
Results
Between July 1996 and September 1997, 56 patients were initially introduced into the study in two institutions (Hospital Clinico Universitario in Valencia and Hospital Universitario San Carlos in Madrid). Two patients were found ineligible a posteriori (previous paclitaxel treatment as adjuvant therapy in one patient and no progression of the disease after the previous chemotherapy in another). The remaining 54 patients were considered fully eligible and assessable with respect to response and toxicity. The characteristics of these 54 patients are presented in Table 1 .
Most patients were postmenopausal, had presented with involvement of three or more organ systems, and had visceral disease. The median age of patients was 53 years and six of them were older than 70 years. Two of the younger patients who were in complete response 20 (37) 11 (20) 15 (28) 8 (15) after the fourth course of therapy were subjected to consolidation with high-dose chemotherapy and peripheral blood stem-cell support. The median number of courses given per patient in the remaining 52 cases was 6 (range 1-8). All patients have finished treatment, and all but two have died or presented with progressive disease after the end of paclitaxel-vinorelbine treatment. Two patients received only one course of treatment because of clear progression of the disease by the end of the first treatment course. Eighteen patients tolerated eight courses of therapy without significant toxicity. The mean delivered dose intensity received by the patients was 93% of the planned dose intensity (42 mg/m 2 /week of paclitaxel and 9.3 mg/m 2 /week of vinorelbine).
Anti-tumour activity
A radiologist and a clinical oncologist, both of whom were independent of the investigation team, confirmed responses. Six complete and nineteen partial responses were observed in the fifty-four eligible patients (overall response rate in intention-to-treat analysis: 46%, 95% confidence interval (95% CI): 33%-60%). Eighteen patients had stable disease as best response. In six of these patients (11% of the total study group), the stabilisation lasted for six or more months. The remaining 11 patients had progressive disease during the three initial cycles of paclitaxel plus vinorelbine. Responses were observed in all sites: liver (8 of 20 patients, 40%), lung (7 of 17 patients, 41%), skin and soft tissues (12 of 24 patients, 50%) and lymph nodes (5 of 10 patients, 50%). Excluding the two patients who were transferred to a consolidation program of high-dose chemotherapy, the median duration of response was 24 weeks and the median time to progression 28 weeks. The response rate was similar in the two participating institutions (8 of 20 or 40% and 17 of 34 or 50%, in Valencia and Madrid, respectively).
As shown in Table 2 , the activity of the combined paclitaxel and vinorelbine therapy correlated with the extent of prior chemotherapy for metastatic disease and even those patients with two prior chemotherapy regimens obtained a clinically relevant response rate. The response rate among the 13 patients with primary anthracycline resistance (no response or progression during prior anthracycline treatment) was 46%.
Toxicity

Haematological toxicity
Since no nadir of CBC counts were routinely performed, the values recorded correspond mainly to those seen on day 21 of the treatment cycle, except for a few patients who were visited between cycles usually because of fever. Myelosuppression was mild and limited mainly to the oldest patients (>70 years) and/or to those patients with prior extensive chemotherapy. CTC grades 3-4 neutropenia were observed in 12%/28% of 54 patients and 10%/23% of 328 courses of treatment, respectively. Nine of fifty-four patients (17%) had neutropenic fever in fifteen of the three hundred twenty-eight courses administered (5% of total). Toxic deaths due to neutropenic infection did not occur, since the neutropenic period was short (median: 4 days from admission to the hospital). Grade 3 anaemia was seen in two patients and grade 3 thrombocytopenia in two others.
Extra-haematological toxicity
As shown in Table 3 , CTC grade 2 alopecia was the most frequent side effect of treatment. Peripheral neuropathy was frequent but, except in one patient, only mild. This patient presented with disabling plantar disestesia and pain, exacerbated with each new drug administration, from the fourth course onwards. The plantar pain and disestesia prevented normal deambulation and was ameliorated with cooling of the feed. Treatment was stopped at the sixth course and the symptoms reversed a few weeks later. Phlebitis was a significant problem in 16 patients receiving the combination through a peripheral vein. One patient had vinorelbine extravasation resulting in skin ulceration. Dizziness and syncope were seen in a small percentage of patients and were probably related to the ethanol content of the paclitaxel preparation (Taxol package insert) and the short administration period (one hour). By lengthening the dose administration of paclitaxel to three hours, all patients tolerated the subsequent courses without need for dose reduction. Eleven patients (20% of total population) had the dose reduced by 15% because of febrile neutropenia (nine patients) and severe asthenia (two patients). Three of the patients who presented with neutropenic fever were > 70 years of age and two others had previously received three chemotherapy regimens. The two patients who needed dose reductions due to asthenia were very old (77 and 78 years, respectively), had doxorubicinresistant disease, but had excellent partial responses with the combination therapy. Both were able to continue treatment after dose reduction. No toxic deaths occurred.
Discussion
Our study shows that the combination of paclitaxel and vinorelbine given on day 1 every three weeks is active and well tolerated in metastatic breast cancer patients who had had prior exposure to anthracycline therapy. The anti-tumour activity of the combination is relevant from a clinical point of view. The partial plus complete response rate was 46% and an additional 11% of patients had stabilisation lasting for six or more months. The paclitaxel-navelbine regimen was designed with a clear palliative aim with a view to providing the patients with a reasonable chance of symptom improvement while attempting to minimise impairment of the quality of life. We were particularly aware of the need to prevent the overlapping toxicity expected with the combination of paclitaxel and vinorelbine (i.e.. peripheral neuropathy and neutropenic fever). We try, also, to offer the patients a regimen that is convenient and cost-effective in terms of number of visits and duration of stay in the outpatient clinic.
The toxicity of the regimen, as expected, consisted mainly in neutropenia and peripheral neuropathy but these were mild and well tolerated by the patients, with the exception of the small subset of very aged women included in the trial. The infusion of paclitaxel over one hour, as in other trials [13] , was generally well tolerated and contributes to the simplicity of administration of the regimen and to the reduction of treatment-related costs. However, a few patients had dizziness and/or syncope, probably related to the ethanol content of the paclitaxel formulation. They were able to tolerate further cycles with the same dose of paclitaxel by lengthening the time-course of administration to three hours. Phlebitis, probably related to vinorelbine infusion, was a clinically relevant problem in almost all patients receiving the combination through a peripheral vein and, as such, MBC patients due to receive paclitaxel and vinorelbine ought to have a central catheter in place before the first administration.
The selection of this particular schedule of paclitaxel and vinorelbine (dose and timing of drugs, infusion time, and days of drug administration) was based, mainly, on a number of preclinical and clinical data. The rationale for the use of paclitaxel plus vinorelbine in MBC patients with prior anthracycline exposure is based on the partial lack of cross-resistance of either drug with the anthracyclines. Besides, paclitaxel and vinorelbine seem to have a partial lack of cross-resistance, according to the results of a recent trial by Livingston et al. [14] . In this trial, 40 MBC patients with prior exposure to anthracyclines and paclitaxel were given weekly vinorelbine (starting dose of 35 mg/m 2 /week, actual delivered dose intensity of 27.7 mg/m 2 /week) with filgrastim support. The overall response rate of 25% observed confirms the partial lack of cross-resistance between vinorelbine and anthracyclines while indicating, also, a similar lack of cross-resistance between paclitaxel and vinorelbine.
We selected relatively low doses of paclitaxel and vinorelbine since we were concerned about the possibility of inducing severe peripheral neuropathy and/or high rates of neutropenic fever events. The results of our trial confirm that paclitaxel and vinorelbine can be given together safely at the doses selected with little or no peripheral neuropathy and mild myelosuppression in the majority of patients. In contrast to a similar trial [15] we eliminated the second administration of vinorelbine on day 8 of the course because of our general concerns regarding toxicity, especially myelosupressios. In the Michelotti et al. trial [15] the intention had been to administer paclitaxel on day 1 and vinorelbine on days 1 and 8 every three weeks, but the second dose of vinorelbine was reduced or omitted in 88% of the courses because of grade 4 neutropenia. Confirmatory of our toxicity concerns is the more recent publication by Romero-Acuna et al. [16] which reports on the activity and toxicity of the combination of paclitaxel (135 mg/m 2 over three hours on day 1) and vinorelbine (30 mg/m" on days 1 and 8) administered every four weeks in untreated metastatic breast cancer patients. Grade 4 neutropenia was observed in 35 of these patients (78%) and grade 1-2 peripheral neuropathy in 33 patients (67%). As such, the recommendations of the authors, so as to attenuate haematotoxocity, were that further studies with the combination of paclitaxel plus vinorelbine be conducted but with the addition of haemopoietic growth factors to the regimen or the omission of vinorelbine on day 8 and with the cycles repeated every three weeks. This is, indeed, what our present study effectively explores. Table 4 summarises the results of the studies conducted to date (including the present study) with paclitaxel plus vinorelbine in MBC patients [15] [16] [17] [18] [19] [20] [21] [22] . Despite some differences in dosage and scheduling of paclitaxel and vinorelbine in these studies, the response rates were consistent with a clinically relevant activity of the combination (response rates in the range of 36%-60%, depending on the prognostic characteristics of the patients included in the studies). As in our study, most patients in these trials had previously received anthracyclines, but this was not a negative predictor of response. In the study by Michelotti et al. [15] , the response rate in the subset of patients with anthracycline-resistant disease was similar to that observed in the rest of the patient group. Romero-Acuna et al. [16] observed a 60% response rate in patients who had not had prior chemotherapy for metastatic disease. The response rate in the subset of 22 patients with prior FAC adjuvant chemotherapy was 45%. All these data suggest an additive anti-tumour effect of paclitaxel and vinorelbine in MBC patients. Indeed, the response rate to the combination appears clearly superior to that expected with either drug on its own when used in a similar patient population despite the dose intensities of paclitaxel and vinorelbine in the combined regimens being significantly lower to the dose intensity of the agents administered in monotherapy.
The encouraging activity of the combination in patients truly resistant to anthracyclines is of considerable interest. The inclusion of the combination of paclitaxel and vinorelbine in the design of non cross-resistant regimens for breast cancer both in the metastatic and the adjuvant settings deserves further evaluation.
